AstraZeneca/Daisankyo's heavy ADC welcomes a breakthrough again!

On February 21, AstraZeneca and Daiichi Sankyo announced that Enhertu, an antibody-drug conjugate (ADC) jointly developed by the two parties, achieved positive results in the pivotal Phase 3 trial DESTINY-Breast04

According to public information, Enhertu (trastuzumab deruxtecan, DS-8201) is an ADC drug designed using Daiichi Sankyo's proprietary DXd ADC technology platform

The DESTINY-Breast04 trial announced this time is a global, randomized, open-label, registration phase 3 trial designed to evaluate Enhertu (5.

Patients were randomized 2:1 to receive either Enhertu or chemotherapy, the primary endpoint was PFS in patients with HR-positive disease based on a blinded independent central review (BICR), and key secondary endpoints included all patients (regardless of HR status) based on BICR of PFS, OS in patients with HR-positive disease, and OS in all patients

Image source: Daiichi Sankyo official website

Results showed that DESTINY-Breast04 met its primary endpoint, with Enhertu demonstrating superior PFS compared to standard chemotherapy in previously treated patients with HR-positive, HER2-low metastatic breast cancer

Breast cancer is one of the most common cancers in women worldwide and the most common cause of cancer death in women

However, about 80% of breast cancers are classified as HER2-negative, and in more than 40% of them, cancer cells express HER2 at low levels in the form of surface antigens

It is hoped that the ADC product jointly developed by AstraZeneca and Daiichi Sankyo will make more progress in clinical research and bring clinical benefits to more cancer patients as soon as possible

references:

[1] Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer , Retrieved February 21, 2022, from https:// -releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc.

(Original abridged)